Table A1.

Patient Disposition

Disposition	Patients by Dose Level (mg/kg IV)
	0.3		1.0		2.0		3.0		4.0		5.0		7.0		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Patients enrolled with informed consent															59	100
Patients treated	3	100	8	100	6	100	7	100	7	100	4	100	12	100	47	79.7
Reason for study discontinuation
Adverse event	0		1	12.5	1	16.7	2	28.6	4	57.1	2	50.0	3	25.0	13	27.7
Progressive disease	3	100	6	75.0	4	66.7	5	71.4	3	42.9	2	50.0	6	50.0	29	61.7
Patient did not wish to continue	0		0		1	16.7	0		0		0		1	8.3	2	4.3
No longer required study treatment	0		0		0		0		0		0		0		0
Protocol violation	0		0		0		0		0		0		0		0
Lost to follow-up	0		0		0		0		0		0		0		0
Death	0		0		0		0		0		0		0		0
Ongoing	0		1	12.5	0		0		0		0		0		1	2.1
Other	0		0		0		0		0		0		1	8.3	1	2.1

NOTE. For those patients receiving different study treatment doses between the dose-escalation phase and the long-term safety phase of the study, the assigned dose in long-term treatment phase is reported in the table.

Abbreviation: IV, intravenous.